Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Sana Biotechnology (NASDAQ:SANA – Free Report) had its price target boosted by HC Wainwright from $8.00 to $11.00 in a report ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $7 from $8 and keeps a Buy rating on the shares. While political and rate ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...